Journals / Journal of the Turkish-German Gynecological Association / 2021 / Cilt: 22 - Sayı: 1

Investigation of Catechol-O-methyltransferase (COMT) gene Val158Met polymorphism in ovarian cancer

Pages
42–46
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

No statistically significant relationship was identified among genotypes belonging to the patient and control groups although sample sizes were relatively small and the analysis should be repeated in a larger cohort. (J Turk Ger Gynecol Assoc 2021; 22: 42-6)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Catechol-O-methyltransferase (COMT), the product of the COMT gene, detoxifies the carcinogenic catechol estrogens.
📊
Key Findings & Data:The aim of the present study was to examine the relationship between COMT Val158Met polymorphism and the risk of ovarian cancer.Material and Methods: The study groups consist of 94 individuals as a patients group with ovarian cancer (n=47) and control group (n=47).
💡
Conclusion & Impact:No statistically significant relationship was identified among genotypes belonging to the patient and control groups although sample sizes were relatively small and the analysis should be repeated in a larger cohort. (J Turk Ger Gynecol Assoc 2021; 22: 42-6)
🔬Design:Research Article
📍Scope:2021 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Catechol-O-methyltransferase (COMT), the product of the COMT gene, detoxifies the carcinogenic catechol estrogens. The aim of the present study was to examine the relationship between COMT Val158Met polymorphism and the risk of ovarian cancer.Material and Methods: The study groups consist of 94 individuals as a patients group with ovarian cancer (n=47) and control group (n=47). The allele and genotype frequencies were determined according to Hardy-Weinberg equilibrium (HWE). The allele and genotype frequencies. determined according to HWE. Genetic analysis were performed by real-time-polymerase chain reaction instrument, and the statistical analysis were performed by SPSS program.Results: Although no significant relationship was obtained among groups (p=0.413) regarding COMT gene Val158Met polymorphism, the genotype frequencies for COMT Val158Met (rs4860) polymorphism in groups was homozygote wild type GG genotype 25.5%, heterozygote GA genotype 46.8%, homozygote mutant AA genotype 27.7%.Conclusion: This study is the first to investigate the relationship between ovarian cancer and the Val158Met polymorphism in the COMT gene in a Turkish population. No statistically significant relationship was identified among genotypes belonging to the patient and control groups although sample sizes were relatively small and the analysis should be repeated in a larger cohort. (J Turk Ger Gynecol Assoc 2021; 22: 42-6)

🔖

Cite This Article

AKDENİZ, F. T., YILMAZ, S. G., İSBİR, T., ABAOĞLU, İ. Y., ATTAR, R., BARUT, Z., DALAN, A. B. (2022). Investigation of Catechol-O-methyltransferase (COMT) gene Val158Met polymorphism in ovarian cancer. Journal of the Turkish-German Gynecological Association, Cilt: 22 - Sayı: 1, 42–46. https://ajindex.com/articles/567367

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
  2. Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician 2016; 93: 937-44
  3. Grossman MH, Emanuel BS, Budarf ML. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics 1992; 12: 822-5
  4. COMT catechol-O-methyltransferase [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1312#gene-expression (Access date 18.04.2019
  5. Zhou Q, Wang Y, Chen A, Tao Y, Song H, Li W, et al. Association between the COMT Val158Met polymorphism and risk of cancer: evidence from 99 case-control studies. Onco Targets Ther 2015; 8: 2791-803
  6. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-50
  7. Saito S, Iida A, Sekine A, Miura Y, Sakamoto T, Ogawa C, et al. Identification of 197 genetic variations in six human methyltransferase genes in the Japanese population. J Hum Genet 2001; 46: 529-37
  8. Zou LW, Xu XJ, Liu T, Wang HY, Fan WJ, Wang XH, et al. No association between COMT Val158Met polymorphism and prostate cancer risk: A meta-analysis. Genet Test Mol Biomarkers 2013; 17: 78-84
  9. Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997; 57: 5493-7
  10. Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27: 135-206
  11. Grayson K, Gregory E, Khan G, Guinn BA. Urine biomarkers for the early detection of ovarian cancer-are we there yet? Biomark Cancer 2019; 11: 1179299X19830977
  12. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res 2019; 12: 28
  13. Lin H, Pizer ES, Morin PJ. A frequent deletion polymorphism on chromosome 22q13 identified by representational difference analysis of ovarian cancer. Genomics 2000: 69; 391-4
  14. Goodman JE, Lavigne JA, Hengstler JG, Tanner B, Helzlsouer KJ, Yager JD. Catechol-O-met